On May 14, 2020, President Trump signed Executive Order 13922, which granted the Chief Executive Officer of the United States International Development Finance Corporation expansive authority under the Defense Production Act to mobilize resources and financing in response to the COVID-19 pandemic. The Defense Production Act, enacted in 1950, grants the president exceptional powers to compel private industry to prioritize defense and emergency production. By delegating this authority to the DFC—a development finance agency primarily focused on international investments—the order created a new domestic supply chain mechanism ostensibly designed to increase production and procurement of medical supplies and equipment during the health crisis.

The delegation gave the DFC CEO extraordinary leverage to direct private manufacturing capacity toward COVID-19 response activities. This affected American manufacturers, hospitals, medical device producers, and ultimately patients and healthcare workers competing for scarce resources like ventilators, personal protective equipment, and testing supplies during the pandemic's first surge. The DFC's involvement theoretically allowed the agency to finance and coordinate production mobilization across sectors.

This action exemplifies a pattern across the Trump administration's healthcare approach of centralizing control through executive authority while shifting responsibility away from traditional public health institutions. Subsequent actions demonstrate this tendency intensifying—from the 2020 Defense Production Act delegation to recent moves like overturning CDC vaccine recommendations and restricting mifepristone access through telehealth. Rather than strengthening institutional public health capacity, these actions have concentrated emergency powers in executive hands and progressively dismantled preventive healthcare access.

The executive order technically expired as the emergency declaration wound down, though its structural precedent remained. No significant legal challenges to the delegation itself emerged during the pandemic, as the measure enjoyed bipartisan emergency support at the time. However, its use as a template for bypassing conventional agency authority in healthcare matters foreshadowed the more controversial healthcare actions that followed once emergency conditions subsided.